Several EGFR therapies have been approved by the FDA for NSCLC and breast cancer other cancers, including Erlotinib and Gefitinib (first-generation TKIs); Afatinib, Dacomitinib, and Neratinib (second-generation TKIs); Osimertinib, Afatinib, and Lazertinib (third-generation TKIs); JBJ-0412502, BI, BI-4020 (fourth-generation TKIs) [35,41,42]. Here, EGFR is linked to cancer.